60 results
8-K
EX-99.1
CHRS
Coherus Biosciences Inc
9 May 19
First Quarter 2019 Financial Results
4:08pm
of UDENYCA® in 340B hospitals,non-340B hospitals and community oncology clinics is in line with the Company’s expectations.
UDENYCA® launch performance
8-K
EX-99.1
CHRS
Coherus Biosciences Inc
27 Oct 23
Regulation FD Disclosure
4:19pm
include:
Reimbursement support
Patient support
Access support
Commitment to the NPC community
Given the limited resources available to patients … and caregivers contending with NPC, Coherus has launched a new
educational community resource, NPCFacts.com, which includes detailed information about
8-K
EX-99.1
CHRS
Coherus Biosciences Inc
1 Aug 19
Second Quarter 2019 Financial Results
4:23pm
(pegfilgrastim-cbqv) is progressing strongly across all segments (340B hospitals, non-340B hospitals and community oncology clinics), with increased uptake
10-Q
zj1pzmv8di ox5erq
15 Dec 14
Quarterly report
12:00am